GRI Bio will support further development of natural killer T cell modulators. Credit: fernandozhiminaicela from Pixabay.

Vallon Pharmaceuticals has concluded the previously announced merger of its operations with biotechnology firm GRI Bio.

With work on the agreement, announced in December 2022, now complete, the combined entity will operate under the brand of GRI Bio.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will support the further development of GRI Bio’s natural killer T (NKT) cell modulators pipeline, to treat inflammatory, fibrotic and autoimmune diseases.

GRI Bio’s common stock shares will begin trading on the Nasdaq Capital Market on a post-reverse split-adjusted basis under the GRI ticker symbol.

Vallon bought 100% of the outstanding equity interests of GRI Bio (now GRI Bio Operations or Private GRI).

See Also:

This purchase was made through the reverse triangular merger of Vallon’s wholly-owned subsidiary with and into Private GRI, with Private GRI now operating as a wholly-owned subsidiary of Vallon.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Altium Capital had previously invested $2.5m and added a further $12.25 investment immediately before the completion of the merger.

GRI Bio intends to use the funding to finance the advancement of its NKT development pipeline into 2024, to treat inflammatory, fibrotic and autoimmune indications.

It will focus initially on accelerating the development of treatment for idiopathic pulmonary fibrosis.

GRI Bio CEO Marc Hertz stated: “With the completion of the merger and concurrent investment, we are well positioned to realise multiple upcoming catalytic clinical and regulatory milestones that we believe will drive value in the near and long term.”